- XV Eurasian Hematology-Oncology Congress - EHOC 2024
- XIV Eurasian Hematology-Oncology Congress - EHOC 2023
- 8th Eurasian Hematology Oncology Summit
- XIth Eurasian Hematology-Oncology Congress - EHOC 2020
- 7th Eurasian Hematology Oncology Summit
- Xth Eurasian Hematology-Oncology Congress
- Events
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
How I Treat Frontline ALL in 2020: Does Ph-Like Disease Have a Higher MRD+ Rate? Is ChemoRx+/- Rituximab Beneficial for OS/EFS in Burkitt Disease? Do We Need AlloSCT?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
28 views
December 11, 2020
Comments 0
Login to view comments.
Click here to Login
Leukemia